Attempts to make sense of the antiphospholipid syndrome

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 1, 2007, Pages 1-4

  Vermylen, Jos ^a   Carreras, L O ^a   Arnout, J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E RECEPTOR 2; ARACHIDONIC ACID; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; FC RECEPTOR; HEPARIN PLATELET FACTOR 4 ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; LIPOPROTEIN RECEPTOR; LUPUS ANTICOAGULANT; OKT 3; PHOSPHOLIPID; PROSTACYCLIN; SERUM ALBUMIN; THROMBOPLASTIN; THROMBOXANE; THYROID PEROXIDASE ANTIBODY;

ABORTION; ADULT; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; BLEEDING; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETAL CALF SERUM; FETUS DEATH; FETUS WASTAGE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFARCTION; NONHUMAN; PLACENTA PERFUSION; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RADIOIMMUNOASSAY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA;

ANIMALS; ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; BIOMEDICAL RESEARCH; EPOPROSTENOL; FEMALE; HEMATOLOGY; HISTORY, 20TH CENTURY; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; LUPUS COAGULATION INHIBITOR; PLATELET ACTIVATION; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOSIS;

EID: 33845535489     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02253.x     Document Type: Article

References (44)

1. Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Hemost Thromb 1972; 1: 75-95.
2. Bowie EJW, Thompson Jr JH, Pascuzzi CA, Owen Jr CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963; 62: 416-30.
3. Carreras LO. Thrombosis and thrombocytopenia induced by heparin. Scand J Haematol Suppl 1980; 36: 64-80.
4. Carreras LO, Vermylen J. The lupus inhibitor. Sangre (Barc) 1981; 26: 610-8.
5. Chamone DA, Van Damme B, Carreras LO, Vermylen J. Increased release of vascular prostacyclin-like activity after long-term treatment of diabetic rats with Bay g 6575. Haemostasis 1981; 10: 297-303.
6. Lechner K. A new type of coagulation inhibitor. Thromb Diath Haemorrh 1969; 21: 482-99.
7. Nilsson IM, Astedt B, Hedner U, Berezin D. Intrauterine death and circulating anticoagulant ('antithromboplastin'). Acta Med Scand 1975, 197; 153-9.
8. Soulier JP, Boffa MC. Avortement àrépétition, thromboses et anticoagulant circulant antithromboplastine. Trois observations. Nouv Press Med 1980; 9: 859-64.
9. Thiagarajan P, Shapiro SS, De Marco L. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest 1980; 66: 397-405.
10. Carreras LO, Defreyn G, Machin SJ, Vermylen J, Deman R, Spitz B, Van Assche A. Arterial thrombosis, intrauterine death and 'lupus'anticoagulant: Detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981; i: 244-6.
11. Brosens I, Dixon HG, Robertson WB. Fetal growth retardation and the arteries of the placental bed. Br J Obstet Gynaecol 1977; 84: 656-63.
12. De Wolf F, Robertson WB, Brosens I. The ultrastructure of acute atherosis in hypertensive pregnancy. Am J Obstet Gynecol 1975; 123: 164-74.
13. De Wolf F, Carreras LO, Moerman P, Vermylen J, Van Assche A, Renaer M. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am J Obstet Gynecol 1982; 142: 829-34.
14. Carreras LO, Vermylen J, Spitz B, Van Assche A. 'Lupus'anticoagulant and inhibition of prostacyclin formation in patients with repeated abortion, intrauterine growth retardation and intrauterine death. Br J Obstet Gynaecol 1981; 88: 890-4.
15. Carreras LO, Vermylen JG. 'Lupus'anticoagulant and thrombosis - possible role of inhibition of prostacyclin formation. Thromb Haemost 1982; 48: 38-40.
16. Lechner K. Acquired inhibitors in nonhemophilic patients. Haemostasis 1974; 3: 65-93.
17. Lellouche F, Martinuzzo M, Said P, Maclouf J, Carreras LO. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood 1991; 78: 2894-9.
18. Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GRV. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; ii: 1211-4.
19. Gharavi AE, Harris EN, Asherson RA, Hughes GR. Anticardiolipin antibodies: Isotype distribution and phospholipid specificity. Ann Rheum Dis 1987; 46: 1-6.
20. Hughes GR. Autoantibodies in lupus and its variants: Experience in 1000 patients. Br Med J 1984; 289: 339-42.
21. Loizou S, Byron MA, Englert HJ, David J, Hughes GR, Walport MJ. Association of quantitative anticardiolipin antibody levels with fetal loss and time of loss in systemic lupus erythematosus. Q J Med 1988; 68: 525-31.
22. Englert HJ, Derue GM, Loizou S, Hawkins DF, Elder MG, De Swiet M, Walport MJ, Hughes GR. Pregnancy and lupus: Prognostic indicators and response to treatment. Q J Med 1988; 66: 125-36.
23. Arnout J, Huybrechts E, Vanrusselt M, Falcon C, Vermylen J. Detection of lupus-like anticoagulants by an enzyme-linked immunosorbent assay using a partial thromboplastin as antigen; a comparative study. Thromb Haemost 1990; 64: 26-31.
24. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: Beta2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4122-4.
25. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-7.
26. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 178-178.
27. Oosting JD, Derksen RH, Entjes HT, Bouma BN, de Groot PG. Lupus anticoagulant activity is frequently dependent on the presence of beta2-glycoprotein I. Thromb Haemost 1992; 67: 499-502.
28. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal FR. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-32.
29. Amiral J, Bridey F, Dreyfus M, Vissoc AM, Fressinaud E, Wolf M, Meyer D. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95-6.
30. De Gaetano G, Vermylen J, Verstraete M. Platelet aggregation by a specific human immunoglobulin preparation. Thromb Diath Haemorrh 1970; 24: 419-31.
31. De Reys S, Blom C, Lepoudre B, Declerck PJ, De Ley M, Vermylen J, Deckmyn H. Human platelet aggregation by murine monoclonal antiplatelet antibodies is subtype-dependent. Blood 1993; 81: 1792-800.
32. De Reys S, Hoylaerts MF, De Ley M, Vermylen J, Deckmyn H. Fc-independent cross-linking of a novel platelet membrane protein by a monoclonal antibody causes platelet activation. Blood 1994; 84: 847-55.
33. Arnout J, Wittevrongel C, Vanrusselt M, Hoylaerts M, Vermylen J. Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody -beta-2-glycoprotein I complexes on phospholipid surfaces. Thromb Haemost 1998; 79: 79-86.
34. Arnout J. The pathogenesis of the antiphospholipid syndrome: A hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb Haemost 1996; 75: 536-41.
35. Vermylen J, Hoylaerts MF, Arnout J. Antibody-mediated thrombosis. Thromb Haemost 1997; 78: 420-6.
36. Hoylaerts MF, Thijs C, Arnout J, Vermylen J. Recurrent arterial thrombosis linked to autoimmune antibodies enhancing von Willebrand factor binding to platelets and inducing Fc gamma RII receptor-mediated platelet activation. Blood 1998; 91: 2810-7.
37. Avrameas S. Natural autoantibodies: From 'horror autotoxicus'to 'gnothi seauton'. Immunol Today 1991; 12: 154-9.
38. Arnout J, Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost 2003; 1: 931-42.
39. Lutters BC, Meijers JC, Derksen RH, Arnout J, de Groot PG. Dimers of beta2 glycoprotein I mimic the in vitro effects of beta2-glycoprotein I-anti-beta2 glycoprotein I antibody complexes. J Biol Chem 2001; 276: 3060-7.
40. Jankowski M, Vreys I, Wittevrongel C, Boon D, Vermylen J, Hoylaerts MF, Arnout J. Thrombogenicity of beta-2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 2003; 101: 157-62.
41. Lutters BC, Derksen RH, Tekelenburg WL, Lenting PJ, Arnout J, de Groot PG. Dimers of beta2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′. J Biol Chem 2003; 278: 33831-8.
42. Arnout J, Meijer P, Vermylen J. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I. Thromb Haemost 1999; 81: 929-34.
43. 2 GP1 and anti-prothrombin monoclonal antibodies. Thromb Haemost 2001; 86: 584-9.
44. Jennings I, Mackie I, Arnout J, Preston FE. UK National External Quality Assessment Scheme for Blood Coagulation. Lupus anticoagulant testing using plasma spiked with monoclonal antibodies: Performance in the UK NEQAS proficiency testing programme. J Thromb Haemost 2004; 2: 2178-84.